GlassScriptPhysician profile
Jennifer B Mahan
NPI 1871911230
$2,400.15
in general payments reported to CMS, 2019-2025
33 companies · $249 in 2025
The $249 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $368 · 2020: $42.61 · 2021: $125 · 2022: $526 · 2023: $602 · 2024: $488 · 2025: $249.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,339.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,338.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $487.46 | 2019-2024 | Lo Loestrin Fe, Orilissa, Liletta |
| Astellas Pharma US INC | $299.33 | 2023-2025 | Veozah, Myrbetriq |
| Mayne Pharma Commercial LLC | $289.59 | 2022-2025 | |
| Myovant Sciences INC. | $163.64 | 2022 | |
| Exeltis, USA INC. | $136.26 | 2022-2025 | Slynd |
| Baxter Healthcare | $124.88 | 2021 | |
| Biogen, INC. | $120.34 | 2024-2025 | Zurzuvae |
| Sumitomo Pharma America, INC. | $97.66 | 2023-2025 | Myfembree, Gemtesa |
| Pfizer INC. | $71.89 | 2022-2024 | |
| Novo Nordisk INC | $66.34 | 2023-2024 | Wegovy |
| Evofem Biosciences, INC. | $56.12 | 2022 | |
| Merck Sharp & Dohme LLC | $52.41 | 2019-2024 | Gardasil 9, Gardasil |
| Coopersurgical, INC. | $38.96 | 2022-2024 | Wallach Cryosurgical Equipment |
| Vertical Pharmaceuticals, LLC | $34.64 | 2019 | |
| Kerecis Limited | $33.65 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $32.18 | 2023-2024 | Myosure Tissue Removal Device, Acessa Provu System, Coolseal Generator |
| Millicent US INC | $25.97 | 2019 | |
| Roche Diagnostics Corporation | $23.29 | 2019 | |
| Channel Medsystems, INC. | $22.43 | 2023 | |
| Mylan Pharmaceuticals INC. | $20.77 | 2022 | |
| Minerva Surgical, INC | $20.72 | 2022 | |
| Organon LLC | $19.76 | 2023 | Nexplanon |
| Ascend Therapeutics US, LLC | $18.89 | 2022 | |
| Daiichi Sankyo INC. | $18.42 | 2024 | Injectafer |
| Dermavant Sciences, INC. | $16.60 | 2024 | Vtama |
| Allergan, INC. | $16.39 | 2019 | |
| Amgen INC. | $16.24 | 2024 | Prolia, Evenity |
| Boston Scientific Corporation | $15.31 | 2019 | |
| Agile Therapeutics, INC. | $12.71 | 2023 | Twirla |
| Lupin INC. | $12.63 | 2020 | |
| Therapeuticsmd, INC. | $12.50 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $11.11 | 2020 | |
| Amag Pharmaceuticals, INC. | $11.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Mahan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.